This increase in sPD-L1 interferes with the efficacy of anti-PD-L1 antibodies and inhibits T cell activation, thereby contributing to immune resistance and poor outcomes in NSCLC patients. Here, SPDL1 is linked to non-small cell lung carcinoma.